Target intelligence / Profile preview

Nck SH3 domain 1 (Nck SH3.1)

Target
Nck SH3.1
Molecular classification
Adapter protein domain, Src homology 3 (SH3) domain, Scaffold protein module
01

Overview

The **Nck SH3 domain 1** (Nck SH3.1) is the first Src homology 3 domain in the Nck adapter proteins (Nck1 and Nck2), which are composed of one SH2 and three SH3 domains[1][3][6]. The SH3.1 domain specifically binds to proline-rich motifs, notably the PxxDY sequence present in signaling proteins such as the CD3ε chain of the T cell receptor (TCR), and mediates the assembly of signaling complexes crucial for cytoskeletal remodeling and receptor-initiated signaling cascades[1][6]. This binding regulates downstream signaling pathways involved in cell migration, immune synapse formation, and cytoskeletal reorganization[1][3][4][6]. In cancer and immune-related diseases, dysregulation of Nck SH3.1 interactions can lead to altered cell movement and proliferation. While not currently a direct therapeutic drug target, Nck SH3.1 is a validated node for small-molecule or peptide inhibitors aiming to disrupt pathological protein–protein interactions[2].

Other names
Nck1 SH3 domain 1Nck2 SH3 domain 1SH3 domain of Nck1SH3.1 domain of Nck1/Nck2
02

Mechanism of action

Inhibition or modulation of protein–protein interaction between Nck SH3.1 and its proline-rich ligands

03

Biological functions

Signal transductionCytoskeletal organizationCell migrationImmune cell activationCell proliferation
04

Disease associations

CancerInflammationImmune disorders
05

Safety considerations

Potential disruption of actin cytoskeleton regulationImmune modulation effectsOff-target effects due to presence of similar SH3 domains in other proteins

Beyond the preview

Go deeper on Nck SH3 domain 1 (Nck SH3.1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nck SH3 domain 1 (Nck SH3.1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call